$LIXT

Lixte Biotechnology Holdings Inc

  • NASDAQ
  • Biotechnology
  • Health Technology

PRICE

$2.71 ▲9.717%

Last Close

VOLUME

43,706

DAY RANGE

2.2111 - 2.59

52 WEEK

0.45 - 9.5

Join Discuss about LIXT with like-minded investors

profile
@singletary #StockTraders.NET
recently

I'll take more breaks more often so they stocks just go to zero $lixt $veru

141 Replies 7 👍 13 🔥

profile
@Math #StockTraders.NET
recently

$LIXT offering

75 Replies 10 👍 10 🔥

profile
@Chano #StockTraders.NET
recently

$LIXT too expensive locate

95 Replies 9 👍 11 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

$LIXT nice

113 Replies 8 👍 10 🔥

profile
@singletary #StockTraders.NET
recently

$lixt 6m candle there on squeeze

119 Replies 6 👍 7 🔥

profile
@Chano #StockTraders.NET
recently

$LIXT is due for a raise following chronology of their offerings, last time they had an ATM, it's a 1 day wonder player

136 Replies 12 👍 9 🔥

profile
@maletone #StockTraders.NET
recently

watchlist short: $BTCS, $lIXT, $ATHE, $AACG,

106 Replies 7 👍 8 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT hold up please

66 Replies 11 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

hopefully $lixt gives us an opportunity tomorrow

54 Replies 14 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

I hope they keep $LIXT up for tomorrow so we can reshort it

139 Replies 9 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

covering some more $LIXT under 2.10

83 Replies 11 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT doing it too

78 Replies 10 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

will start covering some $LIXT

59 Replies 15 👍 14 🔥

profile
@singletary #StockTraders.NET
recently

$lixt nice pull

86 Replies 7 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

$SENS & $LIXT lower

48 Replies 15 👍 11 🔥

profile
@maletone #StockTraders.NET
recently

would be nice if $LIXT really trapped but doesnt feel like it will

94 Replies 12 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT might break .50

100 Replies 6 👍 11 🔥

profile
@nepestheone #StockTraders.NET
recently

1/5/2022 [9:07 AM] LIXT- similar to NLSP yest i expect crowd then a possible short opp later using 3.50-5 res. If you want to long dips imo 2.40-2.20 support 5 min trend [9:07 AM] MYNZ- watching for a potential pump and short using 20.50-23 resistance they may try to squeezeout first paytience bc blue sky breakout assume 18-17 support from prior run [9:07 AM] RELI- ideally one more retest of 9.50 zone for sub 8 targets

93 Replies 14 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$LIXT feels like it has a bigger float than 4.5 mill

112 Replies 9 👍 13 🔥

profile
@CarlosH-carvan #ivtrades
recently

$LIXT booom

122 Replies 12 👍 6 🔥

SO
@soheil.n #StockTraders.NET
recently

no borrows for me..closest VWAPBLVD is at 3..38 which is based on the 17 m vol day > @maletone said: I'm watching $LIXT

111 Replies 7 👍 10 🔥

BR
@brAli #StockTraders.NET
recently

$lixt im looking to join 3.25 to 3.8

62 Replies 13 👍 12 🔥

profile
@maletone #StockTraders.NET
recently

I'm watching $LIXT

60 Replies 11 👍 9 🔥

Key Metrics

Market Cap

5.56 M

Beta

0.62

Avg. Volume

32.87 K

Shares Outstanding

2.25 M

Yield

0%

Public Float

0

Next Earnings Date

Next Dividend Date

Company Information

lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in

Website:

HQ: ,

Related News